Edgar Cespedes, MD
Cardiovascular Disease · Miami, FLNPI 1356304455
Payments from drug & device makers
Across 340 payments — averaging $195.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$36K
- Esperion Therapeutics, Inc.$14K
- Sanofi-aventis U.S. LLC$11K
- Actelion Pharmaceuticals US, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$848
- Novo Nordisk$455
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$57,65787%
- Travel & lodging$1,2042%
- Food & beverage$7,55011%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 80 | $36,051 |
| Esperion Therapeutics, Inc. | 28 | $14,224 |
| Sanofi-aventis U.S. LLC | 20 | $10,999 |
| Actelion Pharmaceuticals US, Inc. | 97 | $1,728 |
| Regeneron Healthcare Solutions, Inc. | 4 | $848 |
| Novo Nordisk | 26 | $455 |
| GSK | 5 | $378 |
| Impulse Dynamics (USA) Inc. | 3 | $261 |
| AstraZeneca | 11 | $212 |
| Novartis | 10 | $208 |
| Boehringer Ingelheim | 13 | $195 |
| E.r. Squibb & Sons, L.L.C. | 9 | $172 |
| Agepha Pharma FZ LLC | 1 | $171 |
| Kowa Pharmaceuticals America, Inc. | 7 | $122 |
| Amgen | 5 | $95 |
| Johnson & Johnson | 8 | $72 |
| Regeneron | 1 | $61 |
| Lilly USA, LLC | 4 | $55 |
| Baxter Healthcare | 2 | $51 |
| Edwards Lifesciences | 1 | $50 |
| Corcept Therapeutics | 1 | $24 |
| Bayer | 1 | $24 |
| Exact Sciences | 1 | $22 |
| Abbott | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,516 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 21 | $478,087 |
| OpsumitMacitentan | 37 | $454,043 |
| EliquisApixaban | 307 | $374,076 |
| VascepaIcosapent Ethyl | 469 | $309,369 |
| OzempicSemaglutide | 201 | $271,710 |
| XareltoRivaroxaban | 237 | $268,173 |
| FarxigaDapagliflozin Propanediol | 233 | $245,061 |
| Repatha SureclickEvolocumab | 206 | $215,800 |
| EntrestoSacubitril/Valsartan | 134 | $164,146 |
| JardianceEmpagliflozin | 140 | $152,612 |
| MounjaroTirzepatide | 67 | $98,846 |
| JanuviaSitagliptin Phosphate | 59 | $70,939 |
| Praluent PenAlirocumab | 67 | $66,761 |
| LinzessLinaclotide | 38 | $46,163 |
| Repatha SyringeEvolocumab | 41 | $39,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,728 | $932,13058 claims |
| Novo NordiskOzempic, Rybelsus | $455 | $309,521223 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $212 | $272,188309 claims |
| Johnson & JohnsonXarelto | $72 | $268,173237 claims |
| Boehringer IngelheimJardiance, Tradjenta | $195 | $168,042156 claims |
| NovartisEntresto | $208 | $164,146134 claims |
| Lilly USA, LLCMounjaro, Trulicity | $55 | $119,87780 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $378 | $62,60976 claims |
| AmgenProlia | $95 | $30,27017 claims |
| Sanofi-aventis U.S. LLCMultaq | $10,999 | $22,27411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Miami
- Jonathan FialkowMiami$2.6M
- Melvin Martinez-CastrillonMiami$1.6M
- Theodore FeldmanMiami$637K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.